Genotoxic stress-induced expression of p53 and apoptosis in leukemic clam hemocytes with cytoplasmically sequestered p53

Cancer Research

Volumn 68, Issue 3, 2008, Pages 777-782

  Böttger, Stefanie ^a   Jerszyk, Emily ^a   Low, Ben ^a   Walker, Charles ^a  

^a UNIVERSITY OF NEW HAMPSHIRE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLUTININ; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; HEAT SHOCK PROTEIN 70; MITOXANTRONE; PROTEIN P53;

APOPTOSIS; ARTICLE; BLOOD CELL; CELL NUCLEUS TRANSPLANTATION; CLAM; CONTROLLED STUDY; CYTOPLASM; DNA DAMAGE; GENOTOXICITY; IN VITRO STUDY; IN VIVO CULTURE; LEUKEMIA CELL; MYA; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRESS; TUMOR; WHEAT;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; ETOPOSIDE; FATTY ACIDS, UNSATURATED; HEMOCYTES; HUMANS; LEUKEMIA; MITOXANTRONE; MOLECULAR SEQUENCE DATA; MYA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 38849126304     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0968     Document Type: Article

References (48)

1. 2 arrest in response to topoisomerase II inhibitors: the role of p53. Cancer Res 2003;63:4074-81.
2. Lutzker SG, Levine AJ. Apoptosis and cancer chemotherapy. Cancer Treat Res 1996;87:345-56.
3. Blagosklonny MV, El-Deiry WS. Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer 1998;75:933-40.
4. Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL. The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem 2002;277:16547-52.
5. Moll UM, Wolff S, Speidel D, Deppert W. Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol 2005;17:631-6.
6. Arima Y, Nitta M, Kuninaka S, et al. Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J Biol Chem 2005;280:19166-76.
7. Kelley ML, Winge P, Heaney JD, et al. Expression of homologues for p53 and p73 in the softshell clam (Mya arenaria), a naturally-occurring model for human cancer. Oncogene 2001;20:748-58.
8. Walker C, Böttger S, Low B. Mortalin-based cytoplasmic sequestration of p53 in a non-mammalian cancer model. Am J Pathol 2006;168:1526-30.
9. Kaul SC, Deocaris CC, Wadhwa R. Three faces of mortalin: A housekeeper, guardian and killer. Exp Gerontol 2007;42:263-74.
10. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A 1992;89:7262-6.
11. Moll UM, LaQuaglia M, Benard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A 1995;92:4407-11.
12. Nagpal J, Jamoona A, Gulati ND, et al. Revisiting the role of p53 in primary and secondary glioblastomas. Anticancer Res 2006;26:4633-9.
13. Wadhwa R, Taira K, Kaul SC. An Hsp70 family chaperone, mortalin/mthsp70/PBP74/Grp75: what, when, and where? Cell Stress Chaperones 2002;7:309-16.
14. Kaul SC, Duncan E, Sugihara T, Reddel RR, Mitsui Y, Wadhwa R. Structurally and functionally distinct mouse hsp70 family members Mot-1 and Mot-2 proteins are encoded by two alleles. DNA Res 2000;7:229-31.
15. Nikolaev AY, Li M, Puskas N, Qin J, Gu W. Parc: a cytoplasmic anchor for p53. Cell 2003;112:29-40.
16. Kuperwasser C, Pinkas J, Hurlbut GD, Naber SP, Jerry DJ. Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment. Cancer Res 2000;60:2723-9.
17. Kim IS, Kim DH, Han SM, et al. Truncated form of importin a identified in breast cancer cell inhibits nuclear import of p53. J Biol Chem 2000;275:23139-45.
18. Rodriguez-Lopez AM, Xenaki D, Eden TO, Hickman JA, Chresta CM. MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells. Mol Pharmacol 2001;59:135-43.
19. Zhao LY, Liao D. Sequestration of p53 in the cytoplasm by adenovirus type 12 E1B 55-kilodalton oncoprotein is required for inhibition of p53-mediated apoptosis. J Virol 2003;77:13171-81.
20. Wadhwa R, Takano S, Robert M, et al. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J Biol Chem 1998;273:29586-91.
21. Dundas SR, Lawrie LC, Rooney PH, Murray GI. Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol 2005;205:74-81.
22. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-300.
23. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006;127:1323-34.
24. Sible J, Marsh AG, Walker CW. Effect of extrinsic polyamines on post-spawning testes of the sea star, (Asterias vulgaris) (Echinodermata): implications for seasonal regulation of spermatogenesis. Invertebr Reprod Dev 1992;19:257-65.
25. Geyer RK, Yu ZK, Maki CG. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol 2000;2:569-73.
26. Fuster JJ, Sanz-Gonzalez SM, Moll UM, Andres V. Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med 2007;13:192-9.
27. Marx J. Oncology. Recruiting the cell's own guardian for cancer therapy. Science 2007;315:1211-3.
28. Yu Q. Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy. Drug Resist Updat 2006;9:19-25.
29. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 2006;103:1888-93.
30. Vousden KH, Lane DP. p53 in health and disease. Nat Rev 2007;8:275-83.
31. Buolamwini JK, Addo J, Kamath S, Patil S, Mason D, Ores M. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. Curr Cancer Drug Targets 2005;5:57-68.
32. Chene P. Inhibition of the p53-2 interaction with low molecular weight compounds. Cell Cycle 2004;3:460-1.
33. Mistry AR, Felix CA, Whitmarsh RJ, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005;352:1529-38.
34. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001;268:2764-72.
35. Bossi G, Sacchi A. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck 2007;29:272-84.
36. Wadhwa R, Sugihara T, Yoshida A, et al. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res 2000;60:6818-21.
37. Wadhwa R, Yaguchi T, Hasan MK, Mitsui Y, Reddel RR, Kaul SC. Hsp70 family member, mot-2/mthsp70/ GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. Exp Cell Res 2002;274:246-53.
38. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998;1400:233-55.
39. Tishler RB, Calderwood SK, Coleman CN, Price BD. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 1993;53:2212-6.
40. Knippschild U, Milne DM, Campbell LE, et al. p53 is phosphorylated in vitro and in vivo by the δ and ε isoforms of casein kinase 1 and enhances the level of casein kinase 1 δ in response to topoisomerase-directed drugs. Oncogene 1997;15:1727-36.
41. Fox EJ. Mechanism of action of mitoxantrone. Neurology 2004;63:15-8.
42. De Isabella P, Palumbo M, Sissi C, et al. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. Mol Pharmacol 1995;48:30-8.
43. 1/S and S phase checkpoints. Oncogene 1998;16:721-36.
44. Zaika A, Marchenko N, Moll UM. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation. J Biol Chem 1999;274:27474-80.
45. Zhao Y, Chaiswing L, Velez JM, et al. p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase. Cancer Res 2005;65:3745-50.
46. Kehlenbach RH. In vitro analysis of nuclear mRNA export using molecular beacons for target detection. Nucleic Acids Res 2003;31:e64.
47. Wadhwa R, Taira K, Kaul SC. Can mortalin be a candidate target for cancer therapy? Cancer Ther 2003;1:173-8.
48. 1 cell cycle arrest. Cell Growth Differ 2000;11:149-56.